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Besides the early development of hyperte~~on, 
the Wistar-Okamoto substrain of spontaneously 
hypertensive rats (SH) exhibits an impaired cardiac 
perform~~e ch~acte~zed by decreased chronotropic 
and inotropic responses to&adrenergic stimulation 
f 1,2]. The origin of these alterations in heart mechan- 
ical responses may involve pr~ary or compensator 
mechanisms. A 30% decrease in the total number of 
fi-adrenergic binding sites was recently described in 
cardiac membranes from SH rats as compared to 
normotensive Wistar-foroto (WKY) control rats f3]. 
The affmity of these receptors was found to be iden- 
tical in both groups of animals /3] despite a lesser 
sensitivity of adenylate cyclase activity towards 
cate~hol~ines previously reported in cardiovas~~ar 
tissues from SH rats [4]. 
More recently, a decreased glucagon- and fluoride- 
stimulated adenylate cyclase activity was documented 
in the heart of SH rats [S]. The efficacy and potency 
of secretin and VIP, two parent peptides of glucagon 
which also stimtdate cardiac rn~ch~i~~ properties 
[6-91, is unknown. 
This report compares the stimulation of adenylate 
cyclase activity in stable, highly responsive prepara- 
tions of cardiac membranes from spontaneously 
(genetic) hypertensive SH rats, renal hypertensive rats 
of the Goldblatt ype, and their no~otensive controls 
Abbreviations: VIP, vasoactive intestinal peptide; Gpp(NIi)p, 
guanosine S’-~~,~-i~do~~iphospbate 
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(WKY rats and sham-operated SpragueJZIawley rats, 
respectively). Three types of stimulants were tested: 
(i) Agents acting at the receptor level inc~ud~g the 
fl-adrenergic agonist isoproterenol, and the 
peptides glucagon, secretin, and vasoactive intes- 
tinal peptide; 
(ii) GTP and Gpp(NH)p which act at the guanyl 
regulatory site(s); 
(iii) NaF which directly stimulates the catalytical sub- 
unit. 
A striking reduction in secretin responsiveness was 
the major finding in cardiac membranes from SH rats. 
This contrasted with normal properties of the adenylate 
cyclase activity in similar preparations from renal 
hyperten~ve rats. 
2, Mate&& and methods 
Au strains of rats were bred locally. The main 
characteristics of the male animals used are summa- 
rized in table 1. Goldblatt animals were prepared by a 
stricture on the right renal artery 6 weeks before 
sacrifice. The left kidney was left untouched. The 
corresponding controls were sham-operated. 
After an overni~t fast the rats were sacrificed by 
decapitation. Each heart was carefully dissected out, 
rinced at room temperature with isotonic sodium 
chloride, weighed, and frozen in liquid nitrogen. 
A crude cardiac particuiate fraction was prepared 
with minor modifications of the procedure in [lo]. 
The cardiac tissue was homoge~zed (5%, w/v, 
homogenate) in a 20 mM Tris-HCl, 2 mM dithio- 
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erythreitol, 5 mM MgCls (pH 7.5) buffer. After ftitra- 
tion through two layers of medical gauze the 
homogenate was centrifuged at 520 X g for 10 min. 
The pellet was washed once with the same buffer and 
resuspended in 20 mM Tris-HCl, 5 mM MgClz, 0.25 M 
sucrose (pH 7.5) buffer. An equal volume of the same 
buffer enriched with 2.5 M KC1 was added dropwise. 
The suspension was stirred continuously for 2 h at 
2°C then centrifuged at 37 000 X g for 10 min. The 
pellet was resuspended in a 20 mM Tris-HCl, 2 mM 
dithioerythreitol, 0.25 M sucrose (pH 7.5) buffer, 
washed 3 times in this buffer by centrifugation at 
3 1 000 X g for 5 min and resuspended in a volume of 
the same buffer allowing final cont. 6 mg/protein ml. 
Adenylate cyclase activity was deter~ned with 
minor modifications of the procedure in [ 111: -60 pg 
membrane protein were incubated in 60 ~1 con- 
taining 0.5 mM [w~~P]ATP, 5mM MgC12, 0.5 mM 
EGTA, 1 mM cyclic AMP, 1 mM theophylline, 
10 mM phosph~enol)pyruvate, 30 pg/ml pyruvate 
kinase and 30 mM Tris-HCl, adjusted to pH 7.5. 
Under all conditions tested, the enzymatic kinetics 
were linear for 2 10 ruin at 37’C. In routine assays, 
the reaction was stopped after 10 min by adding 
0.5 ml of a 0.5% sodium dodecylsulfate solution con- 
taining 1.5 mM ATP, 0.5 mM cyclic AMP and 20 000 
cpm cyclic [g3H]AMP. Cyclic AMP was separated 
from ATP by two successive chromatograp~es on
Dowex AGI X 8 and neutral alumina. 
DL-isoproterenol was from Sigma Co. (St Louis, 
MO) and porcine glucagon was from Novo Industri 
(Copenhagen). Natural porcine secretin and VIP were 
essentially pure peptides prepared by Dr Viktor Mutt 
at the Karolinska Institutet (Stockholm) and were 
supplied by the NIH (Bethesda, MD). 
3. Results 
Basal, fluoride-, ~pp~p- and GTP-activated 
adenylate cyclase activities were determined in the 
standard medium assay in section 2. The hormone- 
sensitive activity was measured in the presence of 
10” M GTP as orientation experiments indicated 
that neither a fl-adrenergic agonist, nor glucagon, 
secretin or VIP could activate the enzyme in’the 
absence of a guanyl triphosphate nucbotide. 
All the agents tested proved to be effective stimuli 
of cardiac adenylate cyclase activity (fig. 1 and table 1). 
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Fig.1. Dose-effect curves of adenylate cyclase activity stimulated by isoproterenol (left panel), glucagon (middle panel) and 
secretin (right panel), in the presence of 10-I M GTp, in cardiac membranes from WKY rats (white circles) and SH rats (black 
circles). Each curve is the mean f SEM of 5 expt. The dashed lines indicate that values obtained in the presence of lo-’ M GTP 
alone. 
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Table 1 
General characteristics of types of male hypertensive rats and their corresponding controls 
Group WKY rats SH rats Sham-operated Goldblatt rats 
Strain Wistar Wistar Sprague-Dawley Sprague-Dawley 
Substrain Kyoto(WKY) SH - - 
Age (weeks) 14 14 18 18 
Body weight 
(in g) 273t 4 272 f 12 395 f 9 377 f 14 
Systolic blood pressure 
(in mm Hg) 132+ 5 200 f 6a 107t 4 183 f 8a 
Heart weight 
(in mg) 830 + 20 920 f 20 922 f 45a 1164t44a 
a Significantly higher (at P < 0.05) than values obtained with corresponding normotensive con- 
trols by the Student’s f-test 
Means f SEM from 5 animals 
There was not significant difference in the magnitude 
of the stimulations observed with lo-’ M GTP, 
lo-’ M Gpp(NH)p and 10 mM NaF in heart mem- 
branes from normal and hypertensive animals of both 
the Wistar-Kyoto and the Sprague-Dawley strains. 
Dose-effect curves of adenylate cyclase activity 
stimulated by isoproterenol, glucagon and secretin 
indicate that the 3 agents were potent activators in 
the presence of lo-’ M GTP. However, maximal 
effects of isoproterenol, glucagon and secretin were 
lower in membranes from SH rats than in control 
WKY rats with no modification in the concentration 
required for half-maximal efficacy. The stimulatory 
effect exerted by 3 X 10” M VIP was also signif- 
icantly lower in SH rats as compared to WKY rats 
(table 1). The secretin responsiveness was by far the 
most affected (fig. 1 and table 1) being statistically 
lower (P < 0.05) than that observed with the other 
stimulatory agents. 
In renal hypertensive Goldblatt rats on the con- 
trary, the maximal stimulatory effects of isoproterenol, 
glucagon and secretin were identical with those 
observed in sham-operated rats of the Sprague-Dawley 
strain (table 2). The amine and peptide concentrations 
Table 2 
Stimulation of adenylate cyclase activity in cardiac membranes from spontaneously hypertensive (SH) 
and Goldblatt renal hypertensive rats and their corresponding controls 
Additions (M) WKY rats SH rats Sham-operated Goldblatt rats 
GTP 1o-5 8+ 2 8* 2 SC 1 4+ 1 
GPP(NH)P 1o-5 100 f 15 87 * 10 149 * 18 107 f 24 
NaF 1o-2 503 f 60 470 f 33 610 * 22 560 f 20 
DL-Isoproterenol 1o-4 187 +_ 15 123 * lla 104 f 18 93+ 1s 
Glucagon 10-” 189 f 25 114 f 15a 86 f 12 93 + 13 
Secretin 1O-5 133 * 11 37 + 5a 111+ 12 97 + 15 
VIP 3 x 1o-6 46+ 5 20 f 4a sot 9 48? 8 
a Significantly lower (at P < 0.05) than values obtained with corresponding normotensive controls, by 
the Student’s t-test 
The data are expressed as pmol cyclic AMP formed .min-’ .mg protein-’ and were obtained after 
subtracting the basal unstimulated value. Means f SEM from 5 animals. The mean basal activities 
were 47 f 6,43 i: 6,62 f 7 and 48 f 5 in cardiac membranes from WKY, SH, shamoperated and 
Goldblatt rats, respectively 
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required for half-maximal efficacy were also equiv- 
alent in both groups and similar to those observed in 
the Wistar-Kyoto strain (data not shown). In addition, 
noticeable differences in the maximal efficacy of 
stimuli were observed between preparations from 
control normotensive rats of the Wistar-Kyoto and 
Sprague-Dawley strains (table 2). 
4. Discussion 
The present data demonstrate hat: 
1. In two different strains, rat cardiac adenylate 
cyclase activity was GTPdependently stimulated 
by secretin and VIP as well as by the two well 
established stimulatory agents isoproterenol and 
glucagon; 
2. Peptide- and isoproterenol-stimulated adenylate 
cyclase activities were lowered in adult SH rats with 
no apparent alteration in either guanyl nucleotide 
regulatory sites or ~uoride-~nsitive sites. The 
reduction in maximal responses to the hormone 
peptides and to the fl-adrenergic agonist, with no 
change in their efficacy, suggests a decrease in the 
number of the corresponding receptors. In this 
respect, he 34Y0 lowering of maximal isoproterenol 
binding sites of cardiac membranes reported [3]; 
stimulation of adenylate cyclase activity in SH rats 
(table 1) compared well with the 30% reduction in 
dihydroalprenolol binding sites of cardiac mem- 
branes reported [3]; 
3. The ~cret~-striated adenylate cyclase activity 
was more reduced than that observed in the 
presence of any other agent; 
4. Taken together, these results uggest that secretin, 
VIP and glucagon functional receptors represented 
distinct entities, in spite of the numerous tructural 
homolo~es between the 3 peptides [12]. This 
situation is reminiscent of the existence of distinct 
glucagon and secretin-VIP receptors in liver 1131 
and distinct secretin- and VIP-preferring receptors 
in the exocrine pancreas [ 141; 
5. The reduced hormone sensitivity of adenylate 
cyclase appeared specific to the spont~eou~y 
hypertensive rat as the same system was free of 
such alterations in animals with renal hyperten- 
sion exhibiting similar high systolic blood pressure 
and cardiac muscle hypertrophy. Thus, impair- 
ment of cardiac hormone-sensitive adenylate 
cyclase activity appeared to be part of the syn- 
drome in SH rats and not a consequence of myo- 
cardial strain. 
The preferential reduction in the potency of 
secretin and VIP as activators of adenylate cyclase in 
cardiac membranes from SH rats raises the dual 
question of its bearing on cardiac muscle activity and 
on the role of secretin and VIP in the pa~ogenesis of
the syndrome. Data concerning the effects of secretin 
and VIP on heart metabolism are scarce: both peptides 
share with glucagon and isoproterenol stimulating 
properties on cardiac activity [6-91 but the physio- 
logical significance of these effects remains to be 
establ~hed. In addition, the regulation of hormone 
receptors in heart is largely unknown, e.g., the adapta- 
tion of the number of receptors in response to altera- 
tion in the level of circulating hormone or in the 
activity of sympathetic nnervation. A few lines of 
evidence allow, however, some speculation on a 
possible involvement of secretin and VIP in the bio- 
chemical events leading to hypertension i  SH rats. 
The 3 prevalent hypotheses accounting for the 
development of hypertension i  SH rats might indeed 
imply a contribution of these peptides: 
1. The capacity of the kidney to excrete salt and 
water in proper relation to their intake is reduced 
[ 151. Secretin and VIP are known to influence 
several water movements. Secretin inhibits the 
reabsorption of II+ and Na’ in the human kidney 
[ 161. Secretin and VIP stimulate bicarbonate and 
water secretion from the exocrine pancreas [17]. 
VIP stimulates fluid secretion from gut [ 181. VIP 
is present in large amounts in the hypothalamus 
[ 191 and also in the posterior pituitary [20] where 
it activates aparticulate adenylate cyclase [21]. 
This might provide a link between VIP and vaso- 
pressin, renin, ~giotens~ 2, and ACTH secretion 
I221. 
2. SH rats suffer from an hyperactivity of the sym- 
pathoadrenal system [23]. The candidate neuro- 
transmitter VIP could modulate neuronal trans- 
mission in both central and sympa~etic nervous 
systems [24,25]. VIP is also reported to activate 
adenylate cyclase in adrenal glands [26]. A role for 
secretin in the nervous ystem is not yet docu- 
mented. 
3. There is an enhanced vasoconstrictor response of 
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vascular smooth muscle in SH rats. VIP is a potent 
vasodilator [27] which probably acts through the 
rich VIPergic innervation of blood vessels. Similarly, 
secretin provokes a vasodilatation of splanchnic 
vessels [28]. 
From our data and from the latter considerations, 
it is tempting to suggest that a low responsiveness of 
adenylate cyclase to secretin and VIP could alter the 
mechanical performance of the myocardium in SH 
rats and that this class of peptides might be involved 
in the pathogenesis of hypertension i  these animals. 
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